Literature DB >> 19845001

Triple light chain antibodies: factors that influence its formation in cell culture.

Natalia Gomez1, Abigail R Vinson, Jun Ouyang, Mary D H Nguyen, Xiaoying-Nancy Chen, Vikas K Sharma, Inn H Yuk.   

Abstract

THIOMABs are recombinant antibodies engineered with reactive cysteines, which can be covalently conjugated to drugs of interest to generate targeted therapeutics. During the analysis of THIOMABs secreted by stably transfected Chinese Hamster Ovary (CHO) cells, we discovered the existence of a new species--Triple Light Chain Antibody (3LC). This 3LC species is the product of a disulfide bond formed between an extra light chain and one of the engineered cysteines on the THIOMAB. We characterized the 3LC by size exclusion chromatography, mass spectrometry, and microchip electrophoresis. We also investigated the potential causes of 3LC formation during cell culture, focusing on the effects of free light chain (LC) polypeptide concentration, THIOMAB amino acid sequence, and glutathione (GSH) production. In studies covering 12 THIOMABs produced by 66 stable cell lines, increased free LC polypeptide expression--evaluated as the ratio of mRNA encoding for LC to the mRNA encoding for heavy chain (HC)--correlated with increased 3LC levels. The amino acid sequence of the THIOMAB molecule also impacted its susceptibility to 3LC formation: hydrophilic LC polypeptides showed elevated 3LC levels. Finally, increased GSH production--evaluated as the ratio of the cell-specific production rate of GSH (q(GSH)) to the cell-specific production rate of THIOMAB (q(p))--corresponded to decreased 3LC levels. In time-lapse studies, changes in extracellular 3LC levels during cell culture corresponded to changes in mRNA LC/HC ratio and q(GSH)/q(p) ratio. In summary, we found that cell lines with low mRNA LC/HC ratio and high q(GSH)/q(p) ratio yielded the lowest levels of 3LC. These findings provide us with factors to consider in selecting a cell line to produce THIOMABs with minimal levels of the 3LC impurity. (c) 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19845001     DOI: 10.1002/bit.22580

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  8 in total

1.  Analytical characterization of a monoclonal antibody therapeutic reveals a three-light chain species that is efficiently removed using hydrophobic interaction chromatography.

Authors:  Rachel B Wollacott; Paul L Casaz; Trevor J Morin; H Lily Zhu; Roger S Anderson; Gregory J Babcock; John Que; William D Thomas; Sadettin S Ozturk
Journal:  MAbs       Date:  2013-08-19       Impact factor: 5.857

Review 2.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

Review 3.  Therapeutic applications of an expanded genetic code.

Authors:  Sophie B Sun; Peter G Schultz; Chan Hyuk Kim
Journal:  Chembiochem       Date:  2014-07-18       Impact factor: 3.164

4.  Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Authors:  Jared L Spidel; Earl F Albone; Xin Cheng; Benjamin Vaessen; Sara Jacob; Andrew Z Milinichik; Arielle Verdi; J Bradford Kline; Luigi Grasso
Journal:  MAbs       Date:  2017-05-25       Impact factor: 5.857

5.  Characterization of monoclonal antibody size variants containing extra light chains.

Authors:  Connie Lu; Dandan Liu; Hongbin Liu; Paul Motchnik
Journal:  MAbs       Date:  2012-12-19       Impact factor: 5.857

Review 6.  Methods for site-specific drug conjugation to antibodies.

Authors:  Christopher R Behrens; Bin Liu
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 7.  Therapeutic applications of genetic code expansion.

Authors:  Yujia Huang; Tao Liu
Journal:  Synth Syst Biotechnol       Date:  2018-10-03

8.  Cysteine-to-lysine transfer antibody fragment conjugation.

Authors:  Nafsika Forte; Irene Benni; Kersti Karu; Vijay Chudasama; James R Baker
Journal:  Chem Sci       Date:  2019-10-11       Impact factor: 9.825

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.